Brii Biosciences' (HKG:2137) attributable loss narrowed to 148.1 million yuan in the first half from 280.5 million yuan in the year-ago period, according to a Thursday filing with the Hong Kong bourse.
Loss per share at the drug company narrowed to 0.20 yuan from 0.38 yuan a year earlier.
The company's other income fell to 28.1 million yuan from 70.9 million yuan in the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.